My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Penumbra, Inc. Common Stock (NY:PEN)

357.68 +2.24 (+0.63%)

Official Closing Price Updated: 6:30 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

A Look Into Penumbra Inc's Price Over Earnings ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

A Look Into Penumbra Inc's Price Over Earnings ↗

October 03, 2025

Via Benzinga

What To Expect From Penumbra’s (PEN) Q3 Earnings

November 03, 2025

Medical device company Penumbra (NYSE:PEN) will be reporting results this Wednesday after the bell. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

Why Penumbra (PEN) Shares Are Falling Today

October 28, 2025

Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results from its landmark STORM-PE randomized controlled trial. The study found that...

Via StockStory

Topics Artificial Intelligence

Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings) ↗

October 27, 2025

Via Benzinga

Can Penumbra's 'Landmark' Study Vs. Blood Thinners Change Guidelines? ↗

October 26, 2025

Penumbra pitted its device, Lightning Flash, with blood thinners vs. blood thinners, alone, in patients with pulmonary embolism.

Via Investor's Business Daily

Peering Into Penumbra Inc's Recent Short Interest ↗

October 02, 2025

Via Benzinga

What Does the Market Think About Penumbra? ↗

August 12, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Penumbra Stock In The Last 10 Years ↗

October 24, 2025

Via Benzinga

Penumbra (PEN) Stock Trades Up, Here Is Why

October 08, 2025

Shares of medical device company Penumbra (NYSE:PEN) jumped 3.2% in the morning session after Needham upgraded the stock to 'Buy' from 'Hold' and set a price target of $326.

Via StockStory

Topics World Trade

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 08, 2025

Via Benzinga

9 Analysts Assess Penumbra: What You Need To Know ↗

October 07, 2025

Via Benzinga

3 Low-Volatility Stocks We Approach with Caution

October 06, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

Topics Economy

$100 Invested In Penumbra 10 Years Ago Would Be Worth This Much Today ↗

October 03, 2025

Via Benzinga

Merit Medical Systems, ICU Medical, and Penumbra Stocks Trade Down, What You Need To Know

September 25, 2025

A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential...

Via StockStory

Topics World Trade

Here's How Much $100 Invested In Penumbra 10 Years Ago Would Be Worth Today ↗

September 23, 2025

Via Benzinga

1 High-Flying Stock to Own for Decades and 2 We Turn Down

September 16, 2025

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

Oscar Health, Penumbra, DexCom, Merit Medical Systems, and HCA Healthcare Shares Are Falling, What You Need To Know

September 10, 2025

A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.

Via StockStory

Topics Economy

3 Healthcare Stocks We’re Skeptical Of

September 08, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

3 Mid-Cap Stocks We Steer Clear Of

September 04, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 03, 2025

Via Benzinga

This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 03, 2025

Via Benzinga

Deep Dive Into Penumbra Stock: Analyst Perspectives (9 Ratings) ↗

September 02, 2025

Via Benzinga

This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

September 02, 2025

Via Benzinga

Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2

August 27, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - cardiology,...

Via StockStory

3 Cash-Heavy Stocks We Keep Off Our Radar

August 25, 2025

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining...

Via StockStory

Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance

August 12, 2025

Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.